dMed Company Limited, a China-based clinical contract research organization, reportedly raised $8m in Series A funding.
The round was led by Qiming Venture Capital, with participation from Tairui Investment and ZAI Laboratory.
The company intends to use the funds to expand the assurance and clinical operations teams.
Founded in 2016 by Lingshi Tan, dMed is a contract research organization that provides comprehensive services to biopharmaceutical and medical device companies in China and globally, including advising customers on all aspects of clinical development plan, regulatory strategy, and approval processes, as well as full clinical trial support.
Prior to founding dMed, Dr. Tan was Pfizer’s Vice President of Worldwide Development Operations and Chairman and General Manager of Pfizer (China) Research & Development Co., Ltd.